Pfizer Lowers Targeted Revenues For 2012; Wall Street Remains Skeptical
Executive Summary
With the Wyeth integration well under way, Pfizer did what analysts claimed it was going to do for months - it lowered its 2012 revenue targets to $66 billion-$68.5 billion from $70 billion, the figure it initially projected when it announced the Wyeth merger a year ago. But these figures still tower above Wall Street's expectations
You may also be interested in...
Merck Folds In Schering-Plough, Begins Job Cuts
Merck will cut 15,000 jobs in the first phase of a restructuring program intended to integrate Schering-Plough and save $2.6 billion to $3 billion by 2012.
Merck Folds In Schering-Plough, Begins Job Cuts
Merck will cut 15,000 jobs in the first phase of a restructuring program intended to integrate Schering-Plough and save $2.6 billion to $3 billion by 2012.
Pfizer's Message To Wall Street: We're Doing Things Differently Now
Three months after closing Pfizer's $68 billion acquisition of Wyeth (1"The Pink Sheet" DAILY, Jan. 26, 2009), Pfizer has already integrated both companies' R&D organizations and is now working to achieve steady, predictable, but diversified growth, CEO Jeff Kindler said at a Goldman Sachs health care conference Jan. 6